Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Atrium Therapeutics, Inc. (RNA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.68-0.46%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RNA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance precision cardiology programs via strategic partnerships | Atrium Therapeutics is advancing early-stage precision cardiology programs through partnerships with Bristol-Myers Squibb and Eli Lilly. | Improving | No material progress or setbacks in precision cardiology programs by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
RNA is a clinical-stage biotech, so its multi-year view depends on advancing its pipeline rather than established product sales. The thesis state is insufficient to judge, and confidence in the overall evidence is low.
The valuation evidence is limited: the expectations gap is 0.25, and the pricing tag is marked unjustified, but no peer comparison or clear market assumptions are provided. There is not enough evidence to describe RNA as cheap, fair, or expensive versus peers.
Near term, elevated earnings-miss risk and operating losses are important concerns. Management reported FDA clearance, trial initiation, and first-patient dosing for ATR 1072 by October 27, while progress on ATR 1086 remains less clear. Management cited cash resources through mid-2028, but the October offering and limited financial detail leave runway evidence mixed.
Over the multi-year view, the thesis hinges on clinical progress in ATR 1072 and ATR 1086 and on whether cash resources can support development. Near term, weakening jobs data could weigh on healthcare names, while continued strength or weakness from sector bellwethers such as VRTX, REGN, and MRNA could change the sector backdrop.
RNA has a concrete clinical milestone, but the evidence on pipeline delivery, financing, and near-term earnings remains mixed, leaving the 1-3 year thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “Atrium achieved a second milestone under its global cardiovascular collaboration with BMS in August, triggering a payment of $15 million which will be accounted for in the third quarter financial statements.” “Atrium successfully delivered the first development candidate targeting a cardiology indication under its ongoing collaboration with BMS, triggering a $15 million milestone payment.” Revenue was $3.004 million in 2026-Q2.
Improve earnings and cash flow trajectory | A supporting condition in Atrium Therapeutics, Inc.'s published investment case. The stated target is EPS loss narrows from -$3.59 in 2026 to less negative in 2027. | Intact | EPS loss worsens beyond -$5.85 in FY27 | Diluted EPS: $-1.18 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$3.59 in 2026 to less negative in 2027. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-1.18 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Increase revenue toward commercial viability | A primary condition in Atrium Therapeutics, Inc.'s published investment case. The stated target is Revenue grows above $2 million in FY27. | Intact | Revenue falls below $2 million in FY27 | Revenue: $3.004M FY2026-Q2; GAAP. Published target: Revenue grows above $2 million in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 20263,004,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-5.61 → $-6.45 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-07-25 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-07-26 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-07-27 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-07-28 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-07-29 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-07-30 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-07-31 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-01 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-02 | $-5.85 | $2,666,670 | 1 / 3 |
| 2026-08-03 | $-5.85 | $2,666,670 | 1 / 3 |
| 2026-08-04 | $-5.85 | $2,666,670 | 1 / 3 |
| 2026-08-05 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-06 | $-5.85 | $2,666,670 | 1 / 3 |
| 2026-08-08 | $-5.85 | $2,666,670 | 1 / 3 |
| 2026-08-09 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-10 | $-5.85 | $2,000,000 | 1 / 4 |
| 2026-08-12 | $-5.85 | $2,000,000 | 1 / 4 |
| 2026-08-13 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-14 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-15 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-16 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-17 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-18 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-19 | $-5.61 | $2,666,667 | 1 / 3 |
| 2026-08-20 | $-7.10 | $2,666,667 | 2 / 3 |
| 2026-08-21 | $-7.10 | $2,666,667 | 2 / 3 |
| 2026-08-22 | $-7.10 | $2,666,667 | 2 / 3 |
| 2026-08-23 | $-7.10 | $2,666,667 | 2 / 3 |
| 2026-08-24 | $-7.10 | $2,666,667 | 2 / 3 |
| 2026-08-25 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-08-26 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-08-27 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-08-28 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-08-29 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-08-30 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-08-31 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-01 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-02 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-03 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-04 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-05 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-06 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-07 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-08 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-09 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-10 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-11 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-12 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-13 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-14 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-15 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-16 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-17 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-18 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-19 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-20 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-21 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-22 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-23 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-24 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-25 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-26 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-27 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-28 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-29 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-09-30 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-01 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-02 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-03 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-04 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-05 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-06 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-07 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-08 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-09 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-10 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-11 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-12 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-13 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-14 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-15 | $-7.10 | $4,000,000 | 2 / 3 |
| 2026-10-16 | $-6.68 | $4,000,000 | 2 / 3 |
| 2026-10-17 | $-6.68 | $4,000,000 | 2 / 3 |
| 2026-10-18 | $-6.68 | $4,000,000 | 2 / 3 |
| 2026-10-19 | $-6.68 | $4,000,000 | 2 / 3 |
| 2026-10-20 | $-6.68 | $4,000,000 | 2 / 3 |
| 2026-10-21 | $-6.68 | $4,000,000 | 2 / 3 |
| 2026-10-22 | $-6.68 | $4,000,000 | 2 / 3 |
| 2026-10-23 | $-6.45 | $2,666,667 | 2 / 3 |
| 2026-10-24 | $-6.45 | $2,666,667 | 3 / 3 |
| 2026-10-25 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-10-26 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-10-27 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-10-28 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-10-29 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-10-30 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-10-31 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-11-01 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-11-02 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-11-03 | $-6.45 | $2,666,667 | 3 / 4 |
| 2026-11-04 | $-6.45 | $2,666,667 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.